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Summary
OBJECTIVE: The SENIORLABOR study data were ex-
plored (i) to examine the evolution during senescence of
the differences between measured glycated haemoglobin
(HbA1c) values and the values predicted by using regres-
sion to extrapolate from measured fructosamine levels; (ii)
to scrutinise the relationship between the glycation gap
and insulin resistance using a homeostasis model assess-
ment, and between the glycation gap and a low-grade in-
flammation marker (C-reactive protein serum concentra-
tion); and (iii) to investigate the glycation gap ranges in
relation to triglyceride levels and kidney function.
SUBJECTS AND METHODS: A total of 1432 Swiss indi-
viduals aged >60 years and classified as healthy (547),
prediabetic (701) or diabetic (184) based on their fasting
plasma glucose and HbA1c values were included in the
study. The glycation gap was evaluated and assigned to
one of four categories: <−0.5; −0.5 to <0.0; 0.0 to ≤0.5;
>0.5.
RESULTS: In healthy and prediabetic participants, the
homeostasis model assessment for estimation of insulin
resistance (p <0.01), high-sensitivity C-reactive protein (p
<0.001) and triglyceride (p = 0.02) values tended to in-
crease with increasing glycation gap category and were
highest in the glycation gap category >0.5. Homeostasis
model assessment for estimation of insulin resistance,
high-sensitivity C-reactive protein and triglyceride levels
tended to increase with increasing glycation gap category
and were highest in the glycation gap category >0.5. Sig-
nificant differences (p <0.01) between glycation gap cate-
gories were seen among different high-sensitivity C-reac-
tive protein concentration groups. Interestingly, in diabetic
participants, homeostasis model assessment for estima-
tion of insulin resistance values, triglyceride concentra-
tions and estimation of glomerular filtration values all de-
creased with decreasing glycation gap category. In the
group of participants with a glycation gap >0.5, high-sensi-
tivity C-reactive protein values tended to increase with in-
creasing glycation gap, whereas for participants with type
2 diabetes and in the glycation gap group >0.5, high-sen-
sitivity C-reactive protein levels tended to decrease as the
glycation gap increased. The percentage of participants
with type 2 diabetes mellitus increased from 2% in the gly-
cation gap category <−0.5 to 76% in the glycation gap cat-
egory >0.5. In contrast, the percentage of healthy partici-
pants fell from 85% to 7%.
CONCLUSION: This is the first time that a direct com-
parison of healthy, prediabetic and diabetic participants,
all assessed under identical conditions and using identical
methodology, has clearly demonstrated a different glyca-
tion gap pattern. Thus, we contribute evidence that the
glycation gap might be of interest in the care of diabetic
patients and their prophylaxis, while acknowledging that
more studies are needed to confirm our findings. (Trial
registration number ISRCTN53778569)
Keywords: glycated haemoglobin, glucose metabolism,
glycation gap, prediabetes, type 2 diabetes, senescence
Introduction
The non-enzymatic glycation of proteins through the Mail-
lard reaction is a physiological process which takes place
in plants, animals and humans alike. This posttranslational
linkage between protein amino and guanidino groups and
sugar carbonyl compounds transitions to Amadori and
Heynes intermediates before ending up in a stable state,
i.e. an advanced glycation end product. Glycation affects
the interactions of proteins with specific receptors [1, 2],
(auto-)antibodies [3], protein half-lives, senescence [4] and
protein folding [5, 6]. Oligosaccharide glycan is covalently
attached to polypeptide side chains. This may occur
through co- and/or post-translational glycation/glycosyla-
tion, now possibly thought to be under control of micro-ri-
bonucleic acid [7]. This glycation serves to aid the recogni-
tion of certain cell types. Advanced glycation end products
*
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are responsible for blood vessel malfunction through their
reactions with specific receptors [8]. The stimulation of
receptors for advanced glycation end products by their
agonists activates nuclear factor-kappa B and increases
endothelial permeability to macromolecules, causing kid-
ney impairment [9, 10]. Advanced glycation end products
block nitric oxide, boosting reactive oxygen species and
causing consecutive inflammation [11]. Glucose concen-
trations are similar in the intra- and extracellular compart-
ments due to the glucose T1 channel homeostatic mech-
anism, which is markedly expressed in the microvascular
system of the kidneys. Hyperglycaemic metabolic state
causes an intracellular toxic effect which leads to mi-
crovascular complications with time [12].
The glycation extent of haemoglobin (glycated haemoglo-
bin A1c) is an indicator of plasma glucose levels over the
~100 days prior to a venipuncture, and the laboratory as-
says for its quantification are steadily changing [13, 14].
The remainder of glycoproteins are collectively termed
fructosamines [15], and most of these are glycated albu-
min. Investigations into both HbA1c and fructosamine val-
ues are appropriate for clinical use [16, 17]. The difference
between the measured HbA1c value and the HbA1c value
predicted from fructosamine values is termed the glycation
gap. It has a broad distribution in patients with nephropa-
thy (from −3.0% to 5.5%) [18]. Glycation gap values os-
cillating within >−0.5 and <0.5 were assumed to be in the
tolerable range. A drop below −0.5 was considered meta-
bolically fit, whereas a glycation gap >0.5 was considered
metabolically unfit [19, 20].
Glycation gap evaluations currently comply with the refer-
ence change value criteria for glycaemic control, as docu-
mented by their stability in the follow-up of patients with
type 2 diabetes [21]. To date, the glycation gap ranges in
healthy controls are unknown. It has been suggested that
glycation gap is not associated with chronic kidney disease
in nondiabetic individuals [22].
Dyslipidaemia, a spectrum of quantitative and qualitative
changes in lipids and lipoproteins, is now acknowledged to
accompany the metabolic abnormality of hyperglycaemia
[23], and a low-grade inflammatory background to insulin
insufficiency emerges in the literature [24].
We have recently found laboratory evidence of impaired
glucose metabolism among subjectively healthy elderly
Swiss individuals [25], and with the current data we hope
to improve our understanding by considering the involve-
ment of glycation gap calculations in diabetic organ failure
[18]. Therefore, in the present study we will relate the gly-
cation gap to lipid metabolism, low grade inflammation as
evidenced by high-sensitivity C-reactive protein, and kid-
ney function as estimated by glomerular filtration rates in
primarily healthy seniors, those with prediabetes, and in a
small number of participants with treated type 2 diabetes
mellitus.
Materials and methods
Study population
We conducted a cross-sectional cohort study. Consecutive
subjectively healthy older volunteers aged ≥60 years were
recruited between February 2009 and December 2011 as
part of the SENIORLABOR study (International Standard
Registered Clinical/Social Study Number 53778569), an
ongoing investigation on the Swiss plateau aimed at cre-
ating appropriate reference intervals for several analytes
in older citizens. The study participants were contacted
through newspaper advertisements, clubs and associations
where there was a high probability that the membership
would include healthy older citizens (e.g., mountaineering
clubs, sports clubs) and, for a few participants, through the
personal contacts of those involved in organising the study.
The personal histories of the participants were collected
and anthropometric measurements (body weight, height
and body mass index) were taken. We excluded candidates
presenting overt comorbidities and excessive alcohol con-
sumption. The food intake of participants was confirmed
to be typical of the Swiss midlands and consisted of an
approximate energy consumption per person per day of
2661 kcal (11,135 kJ), composed of 14% proteins, 51%
carbohydrates and 35% fat [26]. The mean body mass in-
dex of the participants was in the upper normal range for
both genders, based on the definition issued by the World
Health Organization. There were no overweight partici-
pants in the cohort. The primary exclusion criteria for the
present study were: current steroid use, thyroid dysfunc-
tion (free-thyroxine level <9 or >19 pmol/l), high-sensi-
tivity C-reactive protein concentration above 10 mg/l, and
being underweight (body mass index <18.5 kg/m2). The
participant inclusion algorithm is illustrated in fig. 1. Out
of 1467 study participants, 35 were excluded due to miss-
ing glycated haemoglobin A1c values. All remaining par-
ticipants (n = 1432, 100%) were included in the study. The
subjects were subdivided into healthy and diabetic partic-
ipants. The glycated haemoglobin A1c values and fasting
plasma glucose levels in the healthy subjects (n = 1248,
87.2%) remained below the cut-off values for diabetes ac-
cording to the current reference intervals (glycated haemo-
globin A1c ≥6.5%, fasting plasma glucose ≥7 mmol/l). The
diabetic subjects (n = 184, 12.8%) were either diagnosed
with type 2 diabetes and receiving treatment or were iden-
tified as diabetics because their laboratory values exceed-
ed the glycated haemoglobin and/or fasting plasma glucose
cut-offs.
Figure 1: Chart representing all the recruited participants, with
those retained and those excluded (n = number of participants).
See text for primary exclusion criteria.GG = glycation gap; T2DM =
type 2 diabetes mellitus
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This study was conducted in accordance with the ethical
guidelines of the 1957 Declaration of Helsinki and was ap-
proved by the cantonal institutional review board (Kan-
tonale Ethikkommission Bern 166/08, Bern, Switzerland).
All participants provided written informed consent.
Biochemical measurements
The venous blood samples were drawn by venipuncture in-
to S-Monovette tubes (Sarstedt, Sevelen, Switzerland) af-
ter an overnight fasting period. The blood samples were
processed (centrifuged, aliquoted and analysed within two
hours or frozen at –80°C at our site) immediately to enable
standardised preanalytics.
Fasting plasma glucose levels were measured using the
enzymatic hexokinase procedure on a Roche Integra 800
(Rotkreuz, Switzerland). Glycated haemoglobin A1c was
measured with International Federation of Clinical Chem-
istry-approved chromatography (high-power liquid chro-
matography D-10, Biorad, Reinach, Switzerland), a testing
system certified by the United States of America National
Glycohemoglobin Standardization Program. This system
has a coefficient of variation of <2.8%, a range in agree-
ment with currently acknowledged requirements [27].
Fructosamine levels were measured using a spectrophoto-
metric assay based on the reduction of nitroblue tetrazoli-
um to formazan and were assayed on an Abbott ARCHI-
TECT (Abbott Switzerland, Baar). Insulin was measured
with an electrochemiluminescence immunoassay (Cobas
6000). Insulin resistance was estimated with the home-
ostasis model assessment index (serum insulin [µU/ml] x
serum glucose [mmol/l] divided by 22.5). The following
homeostasis model assessment index values and cut-offs
were used: ≤2.0 = no insulin resistance, >2.0 to <2.5 = in-
dication for insulin resistance, ≥2.5 to ≤5.0 = insulin re-
sistance likely; values >5.0 are typically seen in patients
with type 2 diabetes mellitus [28]. Triglyceride levels were
measured using an enzymatic colorimetric method on a
Roche Integra 800 (Roche Diagnostics, Rotkreuz, Switzer-
land). Hypertriglyceridaemia was defined as triglyceride
concentrations >1.7 mmol/l (150 mg/dl), in accordance
with the Canadian Cardiovascular Society guidelines [29].
The isotope dilution mass spectrometry-standardised crea-
tinine concentration was determined using a modified Jaffe
method on a Cobas Integra 800 instrument. Commercially
available materials were used for quality control. Glomeru-
lar filtration rates were calculated using cystatin C equa-
tions [30]. The inter-day coefficients of variation for cre-
atinine were 4.27% at 42 µmol/l and 1.96% at 556 µmol/
l. High-sensitivity C-reactive protein levels were measured
using a Siemens ProSpec instrument. Glomerular filtration
rates were estimated using the combined chronic kidney
disease estimation, which uses creatinine and corrected
cystatin C levels (Chronic Kidney Disease Epidemiology
Collaboration equation). The arithmetic mean of the esti-
mated glomerular filtration ratecys was obtained from the
Caucasian, Asian, Paediatric and Adult cohort equation
[31], and the estimated glomerular filtration ratecrea. was
used for the calculation.
The classification of chronic kidney disease used in our
study is based on either measured or estimated glomerular
filtration rates. Chronic kidney disease stages 1 and 2 de-
note normal or slightly reduced kidney function (glomeru-
lar filtration rate ≥90 ml/min/1.73 m2 or 60–89 ml/min/
1.73 m2). In chronic kidney disease stages 3 and 4, func-
tional impairment is moderate (glomerular filtration rate
30–59 ml/min/1.73 m2) or severe (glomerular filtration rate
15–29 ml/min/1.73 m2).
The serum high-sensitivity C-reactive protein concentra-
tions were categorised as low (<1.0 mg/l), average (1.0–3.0
mg/l) or high (>3.0 mg/l), in accordance with the statement
for healthcare professionals from the Centers for Disease
Control and Prevention and the American Heart Associa-
tion [32]. Participants with high-sensitivity C-reactive pro-
tein values >10 mg/l were excluded from the study at the
outset.
The glycation gap for each participant was calculated by
determining the difference between the measured glycated
haemoglobin A1c level and the value predicted from the
fructosamine measurement using the regression equation
(predicted glycated haemoglobin A1c = 3.2426 + (0.01146
x fructosamine level)). Glycation gap values oscillating
within >−0.5 and <0.5 were assumed to be in the tolerable
range. A drop below −0.5 was considered metabolically fit,
whereas a glycation gap >0.5 was considered metabolical-
ly unfit [19]. Therefore, we subclassified participants into
four glycation gap categories: <−0.5, −0.5 to <0.0, 0.0 to
≤0.5, and >0.5.
The current American Diabetes Association reference in-
tervals for the diagnosis of type 2 diabetes mellitus (glycat-
ed haemoglobin A1c ≥6.5%, fasting plasma glucose ≥7.0
mmol/l) were used for this study [33]. We used the base-
line classifications of prediabetes tested by Heianza et al.
[34]. These authors used combinations of four glycated
haemoglobin intervals, A1c 6.0–6.4%, 5.7–6.4%, <6.0%
or <5.7%, and four fasting plasma glucose level intervals,
6.1–6.9 mmol/l, 5.6–6.9 mmol/l, <6.1 mmol/l or <5.6
mmol/l, to create multiple classifications of prediabetes.
Class A referred to a glycated haemoglobin A1c level of
6.0–6.4% combined with a fasting plasma glucose level of
6.1–6.9 mmol/l, and these criteria were predictive of a cu-
mulative risk of developing type 2 diabetes mellitus of as
high as 100% after 5.6 years. Class B used the combination
of glycated haemoglobin A1c 5.7–6.4% and fasting plas-
ma glucose 6.1–6.9 mmol/l. Class C used the combination
of glycated haemoglobin A1c 6.0–6.4% and fasting plas-
ma glucose 5.6–6.9 mmol/l. Classes B and C both resulted
in a similar cumulative risk of developing type 2 diabetes
mellitus of approximately 80%. Class D was defined by the
combination of glycated haemoglobin A1c 5.7–6.4% and
fasting plasma glucose 5.6–6.9 mmol/l, and was predictive
of a cumulative risk of developing type 2 diabetes mellitus
of approximately 50%. Finally, the combinations of gly-
cated haemoglobin A1c <6.0% and fasting plasma glucose
<6.1 mmol/l (class E) and of HbA1c <5.7% and fasting
plasma glucose <5.6 mmol/l (class F) were predictive of an
approximately 0–10% cumulative risk of developing type
2 diabetes mellitus.
The accuracy and precision of our assays complies with
external and internal quality control requirements and is
certified (international standardisation organisation/IEC
17000,5.5 www.seco.admin.ch) by the Swiss commission
for quality assurance in the medical laboratory.
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Data analysis
The statistical analyses were performed using MedCalc for
Windows, version 15.6.2 (MedCalc Software, Ostend, Bel-
gium). The distributions of the analysed variables were
tested using the Shapiro-Wilk test. For a preliminary analy-
sis, the data were logarithmically transformed as appropri-
ate to correct the skewness of the data. Outliers were de-
tected using the Tukey method, in which an outside value
was defined as a value smaller than the lower quartile mi-
nus 1.5 times the interquartile range or larger than the up-
per quartile plus 1.5 times the interquartile range. Three
such values were identified. Since this is a low number
of outliers and since there was no indication of any error,
these outliers were not excluded from the statistical analy-
ses.
The preliminary appraisals revealed a non-normal distri-
bution of the data, so most statistical analyses were per-
formed using rank-based methods, which can be expected
to perform as intended with skew distributions and certain
outliers. Between-group comparisons were performed us-
ing Student’s t-test and the Mann-Whitney test for inde-
pendent samples. Proportions were compared using the χ2
test. To evaluate a possible trend in analyte concentrations
among the four glycation gap categories, the rank-based
Jonckheere-Terpstra test for trends was used to assess pre-
diabetes involving HbA1c and fasting plasma glucose
measurements. Correlations between variables were esti-
mated using Spearman's rank correlation analysis, depend-
ing on the distribution of the researched variable. A p-
value of <0.05 was considered to indicate statistical
significance in all tests.
Results
The clinical laboratory assay intervals of the healthy and
the diabetic participants differed with various degrees of
significance (table 1). Age, body mass index, homeostasis
model assessment index, fasting plasma glucose level, gly-
cation gap, concentrations of high-sensitivity C-reactive
protein, triglyceride and total cholesterol, and estimated
glomerular filtration rate values were clearly increased,
with various degrees of statistically significance, in partic-
ipants with type 2 diabetes mellitus. Please note that the
glycation gap can be either negative or positive (see also
fig. 5 below).
In the cohort of healthy participants, men had significantly
higher body mass index values, homeostasis model assess-
ment indices for insulin resistance, and fasting plasma glu-
cose levels than women (p <0.001), and only slightly high-
er estimated glomerular filtration rate values (p = 0.04),
whereas total cholesterol levels were significantly in-
creased in women (p <0.001). In accordance with this,
within the type 2 diabetic participants we found slightly
higher estimated glomerular filtration rate values in men
than in women (p = 0.045), whereas age (p = 0.01), high-
sensitivity C-reactive protein concentrations (p = 0.03) and
cholesterol levels (p <0.001) were significantly higher in
women. Haemoglobin concentrations did not fall below
11.0 g/dl in any of the participants.
We then explored the extent of serum protein glycation.
We calculated the median values and 95% confidence in-
tervals (CIs) separately for fasting plasma glucose level,
glycated haemoglobin A1c and glycation gap. Healthy par-
ticipants had a mean fasting plasma glucose level of 5.20
mmol/l (95% CI 5.20 to 5.20), a mean glycated haemoglo-
bin A1c of 5.80% (95% CI 5.70 to 5.80), corresponding
to 39.9 mmol/mol as expressed by International Federation
of Clinical Chemistry units, and a mean glycation gap of
−0.10 (95% CI −0.10 to −0.10). Subjects with laboratory
evidence for glucose metabolism impairment, i.e. diabetic
participants, had a mean fasting plasma glucose level of
6.60 mmol/l (95% CI 6.40 to 6.78), a mean glycated
haemoglobin A1c of 6.70% (95% CI 6.60 to 6.80), and a
mean glycation gap of 0.60 (95% CI 0.60 to 0.70).
Detailed results for the homeostasis model assessment
used to estimate insulin resistance, the concentrations of
high-sensitivity C-reactive protein and triglyceride, and the
estimated glomerular filtration rate are presented by gly-
cation gap category in fig. 2. In the healthy participants,
homeostasis model assessment for estimation of insulin
resistance, high-sensitivity C-reactive protein and triglyc-
eride values tended to increase with glycation gap category
Table 1: Baseline characteristics of healthy and diabetic participants.
Healthy
n = 1248
T2DM
n = 184
p-value
Hypertensive/nonhypertensive, % 36/64 53/47 0.02
Smokers/nonsmokers, % 6/94 10/90 0.43
Women/men, % 56/44 33/67 <0.01
Age, years 71.8 (7.78) 74.4 (7.63) <0.001
Age, range 60–99 60–97 –
Body mass index, kg/m2 25.24 (3.62) 27.2 (4.84) <0.001
HOMA-IR 2.11 (1.41) 3.48 (2.70) <0.001
FPG, mmol/l 5.25 (0.51) 6.97 (2.39) <0.001
HbA1c, %* 5.76 (0.32) 6.70 (1.01) <0.001
Glycation gap −0.11 (0.36) 0.72 (0.92) <0.001
hsCRP, mg/l 2.30 (3.98) 3.24 (6.79) <0.01
Triglycerides, mmol/l 1.36 (0.70) 1.81 (1.39) <0.01
Total cholesterol, mmol/l 5.82 (1.11) 5.17 (1.13) <0.001
eGFR, ml/min/1.73 m2 83.4 (16.11) 75.73 (17.80) <0.001
eGFR = estimated glomerular filtration rate; FPG = fasting plasma glucose; HbA1c = glycated haemoglobin A1c; HOMA-IR = homeostasis model assessment for estimation of
insulin resistance; hsCRP = high-sensitivity C-reactive protein; T2DM = type 2 diabetes mellitus Values are mean values. Differences between healthy and diabetic participants
were calculated using Student’s t-test and the χ2 test, as appropriate. * International Federation of Clinical Chemistry: 39.9 mmol/mol (38.8, 39.9) for the healthy, and 49.7 (48.6,
50.8) for the diabetic participants.
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Figure 2: Variations in homeostasis model assessment for estimation of insulin resistance (HOMA-IR), high-sensitivity C-reactive protein
(hsCRP), triglyceride (TG) and glomerular filtration rate levels according to glycation gap category and diabetic status.Statistical box and
whiskers diagram around median values. (A) Differences between healthy (H) and diabetic (D) participants were calculated with chi-square
and Mann-Whitney tests, as appropriate; (B) hsCRP, high-sensitivity C-reactive protein; (C) TG, triglyceride; (D) GFR, glomerular filtration rate.
As can be seen from the figure, in healthy participants, homeostasis model assessment for estimation of insulin resistance (HOMA-IR), high-
sensitivity C-reactive protein (hsCRP) and triglyceride (TG) values increased with glycation gap category (p<0.001). In diabetic participants,
differences between healthy and diabetic participants were calculated with chi-square and Mann-Whitney tests, as appropriate.HOMA-IR,
triglyceride (TG) and estimated glomerular filtration rate (eGFR) values decreased up to glycation gaps ≤0.5, and behaved inversely in the gly-
cation gap category >0.5. High-sensitivity C-reactive protein values increased up to glycation gaps ≤0.5 and behaved inversely in the glycation
gap category >0.5. Dots represent outliers of the four analytes as indicated on the ordinate.
and were highest in the glycation gap category >0.5. Like-
wise, the Jonckheere-Terpstra test revealed a significant
trend towards higher levels in the higher glycation gap cat-
egories (p <0.001). With estimated glomerular filtration
rate, however, no significant trend was apparent (p = 0.32).
In the type 2 diabetic participants, homeostasis model as-
sessment for estimation of insulin resistance, triglyceride
and estimated glomerular filtration rate values tended to
decrease up to a glycation gap ≤0.5, and behaved inversely
in the pathological glycation gap category (glycation gap
>0.5). In addition, the high-sensitivity C-reactive protein
values tended to increase up to a glycation gap ≤0.5 and
behaved inversely when they reached a pathological gly-
cation gap >0.5. When the Jonckheere-Terpstra test was
applied, however, no significant trend was identified (p
>0.05).
Next, we calculated the percentage of healthy and diabetic
participants in each glycation gap category. A χ2 test for
trend analysis revealed a significant trend (p <0.001) to-
wards higher glycation gap levels from the healthy to the
type 2 diabetic participants. In fact, the percentage of par-
ticipants with a glycation gap >0.5 increased sharply, from
2% in healthy subjects to 58% in diabetic subjects, while
the percentage of participants with a glycation gap <−0.5
decreased from 11% in healthy to 1% in diabetic subjects
(fig. 3). We then investigated the glycation gap values in
the healthy participants according to the four baseline clas-
sifications of prediabetes (fig. 4) [35]. Using the Jonck-
heere-Terpstra test, we found a statistically significant
trend towards lower glycation gap levels as the cumulative
risk of developing diabetes decreased (p <0.001), with the
highest glycation gap level in the 100% cumulative risk
group (A).
When we analysed the extent of insulin resistance, we
found 41 (3.3%) healthy and 41 (22.3%) diabetic subjects
with homeostasis model assessments for estimation of in-
sulin resistance >5.0. Of these participants, 25 (61.0%)
healthy and 36 (87.8%) type 2 diabetic subjects had gly-
cation gaps ≥0.0. With regard to hidden inflammation, 221
(17.7%) healthy and 54 (29.5%) diabetic subjects were in
the higher high-sensitivity C-reactive protein level cate-
gory (>3.0 mg/l) (using the Centers for Disease Control
and Prevention / American Heart Association recommen-
dations), and 121 (54.8%) healthy and 52 (96.3%) type 2
diabetic subjects were in the two glycation gap categories
Figure 3: Percentage of participants in each glycation gap catego-
ry. Diabetic participants clearly exhibited a trend towards higher
glycation gap categories. The grey shading darkens as the glyca-
tion gap changes from below zero to above zero, reflecting the im-
pairment of glycaemic control.
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≥0.0. After applying the Clinical Chemistry of Switzerland
guidelines for hypertriglyceridaemia, 245 (19.6%) healthy
and 66 (35.9%) type 2 diabetic participants had elevated
triglyceride levels (>1.7 mmol/l), and among those partici-
pants, 128 (52.2%) healthy and 59 (89.4%) type 2 diabetic
subjects were in the glycation gap categories ≥0.0. When
we analysed the participants according to chronic kidney
Figure 4: Glycation gap values in healthy participants, according
to four baseline classifications of prediabetes defined by FPG and
HbA1c (see text, [33] and [34]). Multiple combinations of FPG and
HbA1c levels are used to present the glycation gap and the impair-
ment of glycaemic control (abscissa). These combinations are: (a)
HbA1c 6.0–6.4% and FPG 6.1–6.9 mmol/l, (b) HbA1c 6.0–6.4%
and FPG 5.6–6.9 mmol/l, (c) HbA1c 5.7–6.4% and FPG 6.1–6.9
mmol/l, (d) HbA1c 5.7–6.4% and FPG 5.6–6.9 mmol/l, (e) HbA1c
<6.0% and FPG <6.1 mmol/l, (f) HbA1c <5.7% and FPG <5.6
mmol/l.The six alphabetic characters represent, from left to right,
increasing impairment of fasting glucose. (e) and (f) are the
healthy groups according to Heianza et al. [34]. Please note that
the glycation gap changes from below zero to above zero as gly-
caemic control deteriorates. Impairment of glycaemic regulation in-
creases from left to right.
disease stage, as determined by estimated glomerular fil-
tration rates, we found 124 (9.9%) healthy and 32 (17.4%)
diabetic subjects within stage 3 or higher, and 62 (50.0%)
apparently healthy and 31 (96.9%) type 2 diabetic partici-
pants were found in the glycation gap categories ≥0.0.
We then assessed associations between fasting plasma glu-
cose level, glycated haemoglobin A1c and glycation gap
through linked non-glycaemic laboratory assays (table 2),
which are important in the diagnosis of type 2 diabetes. Us-
ing Spearman rank correlation analysis, significant corre-
lations between homeostasis model assessment for estima-
tion of insulin resistance and fasting plasma glucose level
(p <0.001), glycated haemoglobin A1c (p <0.001), and gly-
cation gap (p <0.001) in healthy participants became ap-
parent. The association was strongest for fasting plasma
glucose level. However, in the type 2 diabetic participants,
only fasting plasma glucose level was significantly associ-
ated with homeostasis model assessment for estimation of
insulin resistance (p <0.001).
Treatment with metformin may widen the glycation gap
[19]. This prompted us to evaluate how many type 2 dia-
betic participants were treated with metformin. Out of the
184 participants with type 2 diabetes, 54 were taking an-
tidiabetic drugs, including insulin injections, and the par-
ticipants taking metformin had a mean glycation gap of
0.7%.
The measured fructosamine ranges were used to calculate
the corresponding glycated haemoglobin A1c concentra-
tions in each participant (fig. 5). It appears that within
the reference interval of fructosamine used [19], glycated
haemoglobin A1c values were distributed in a narrow
range, whereas outside the reference interval (below or
above it), this distribution spreads substantially.
Table 2: Degree of insulin resistance relating to inflammatory, lipid and kidney clinical chemistry criteria in the healthy, non-diabetic cohort (n = 1248).
HOMA-IR hsCRP Triglycerides Cholesterol eGFR
FPG rs = 0.48
p <0.001
rs = 0.07
p = 0.02
rs = 0.15
p <0.001
rs = -0.08
p <0.01
rs = 0.00
p >0.05
Age 60 to 69 rs = 0.57
p <0.001
rs = 0.15
p <0.001
rs = 0.22
p <0.001
rs = -0.09
p = 0.04
rs = 0.00
p >0.05
Age 70 to 79 rs = 0.41
p <0.001
rs = -0.02
p >0.05
rs = 0.09
p = 0.04
rs = -0.10
p = 0.03
rs = 0.04
p >0.05
Age ≥80 r = 0.35
p <0.001
r = 0.00
p >0.05
r = 0.08
p >0.05
r = -0.04
p >0.05
r = 0.05
p >0.05
HbA1c rs = 0.19
p <0.001
rs = 0.05
p >0.05
rs = 0.12
p <0.001
rs = -0.01
p >0.05
rs = -0.11
p <0.001
Age 60 to 69 rs = 0.16
p <0.001
rs = 0.06
p >0.05
rs = 0.09
p = 0.046
rs = 0.02
p >0.05
rs = -0.03
p >0.05
Age 70 to 79 rs = 0.24
p <0.001
rs = 0.03
p >0.05
rs = 0.13
p <0.01
rs = -0.03
p >0.05
rs = -0.08
p >0.05
Age ≥80 r = 0.12
p >0.05
r = -0.03
p >0.05
r = 0.16
p = 0.01
r = -0.04
p >0.05
r = -0.10
p >0.05
Glycation gap rs = 0.22
p <0.001
rs = 0.16
p <0.001
rs = 0.14
p <0.001
rs = -0.09
p <0.01
rs = -0.03
p >0.05
Age 60 to 69 rs = 0.17
p <0.001
rs = 0.16
p <0.001
rs = 0.12
p = 0.01
rs = -0.05
p >0.05
rs = 0.04
p >0.05
Age 70 to 79 rs = 0.23
p <0.001
rs = 0.17
p <0.001
rs = 0.14
p <0.01
rs = -0.11
p = 0.02
rs = -0.09
p <0.05
Age ≥80 rs = 0.30
p <0.001
rs = 0.17
p = 0.01
rs = 0.20
p <0.01
rs = -0.14
p = 0.04
rs = -0.08
p >0.05
p <0.001 p <0.05 p >0.05
eGFR = estimated glomerular filtration rate; FPG = fasting plasma glucose; HbA1c = glycated haemoglobin A1c; HOMA-IR = homeostasis model assessment for estimation of
insulin resistance; hsCRP = high-sensitivity C-reactive protein HOMA-IR is a measure of insulin resistance, hsCRP reflects systemic inflammation, triglycerides and free choles-
terol reflect lipid homoeostasis, and estimated glomerular filtration rate represents existing kidney function in the healthy cohort. The shading intensity goes from clear (highly
significant) to darker (not significant).
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In the healthy cohort, fasting plasma glucose level was sig-
nificantly correlated with high-sensitivity C-reactive pro-
tein (p = 0.02), triglyceride (p <0.001) and total cholesterol
(p <0.01) levels. Furthermore, glycated haemoglobin A1c
was significantly correlated with triglyceride concentration
(p <0.001) and estimated glomerular filtration rate (p
<0.001). When we analysed the glycation gap among the
healthy participants, we found additional associations with
high-sensitivity C-reactive protein (p <0.001), triglyceride
(p <0.001) and total cholesterol (p <0.01) concentrations
(table 2). The correlation analyses for homeostasis model
assessment for estimation of insulin resistance and the
high-sensitivity C-reactive protein, triglyceride and total
cholesterol concentrations were performed separately for
three arbitrarily defined age groups: 60–69 years, 70–79
years and ≥80 years. As can be seen from table 2, triglyc-
eride levels were most strongly associated with fasting
plasma glucose levels, whereas estimated glomerular fil-
tration rate was most strongly associated with glycated
haemoglobin A1c in the age group >80 years.
Discussion
In a quest to establish reference intervals for the selected
clinical chemistry parameters, including those relevant to
the diagnosis of type 2 diabetes, we recruited healthy res-
idents with presumably uniform lifestyles and dietary pat-
terns [36]. Swiss plateau nutritional habits typically in-
clude the consumption of dairy products and predictable
proportions of protein, fat and carbohydrates. This means
the participants have comparable glycation exposure of tis-
sues and proteins, including the blood plasma components
accessible for laboratory assays.
The estimation of the glycation gap and fructosamine lev-
els [37] has been used in longitudinal studies to predict
complications of diabetes [38], but it also has the potential
for use in patient care and for the monitoring of therapeutic
regimens. In other evaluations of SENIORLABOR data,
we have excluded participants treated for type 2 diabetes
mellitus or with laboratory evidence of metabolic disease.
In this study, however, they are included, and their labora-
tory values are reported and also analysed in relationship to
the healthy cohort, representing the SENIORLABOR con-
fidence intervals. It is possible that biological variation has
had an influence on the interpretation of our report, but
its effect is minimised by the large number of subjects re-
cruited and the resulting statistical power. Variation exists
within consecutive measurements of many laboratory pa-
rameters in the same individual (www.eflm.eu/) [39–41].
It comes as little surprise that the conventional separators
between healthy and diabetic individuals, i.e., fasting plas-
ma glucose, glycated haemoglobin A1c and homoeostasis
model assessment for insulin resistance values, were high-
ly significantly different between the two groups. Our da-
ta further separate the two groups by triglyceride and total
cholesterol concentrations and estimated glomerular filtra-
tion rates. As expected, we observed that neither glycation
gap nor HbA1c were associated with chronic kidney dis-
ease in nondiabetic individuals [22]. We also now report
for the first time the robust physiological importance of
the glycation gap in this context. Our results indicate that
healthy elderly individuals display a significant direct rela-
tionship between glycation gap and homeostasis model as-
sessment-measured insulin resistance, high-sensitivity C-
reactive protein levels, and triglyceride concentrations, and
that this relationship is much stronger than that between
these parameters and glycated haemoglobin A1c or fasting
plasma glucose levels. This fact strongly challenges the
idea that the glycation gap is a spurious empirical measure
of the disagreement between the two indirect estimates of
glycaemic control.
Such an understanding of glycation gap requires an ap-
preciation of the fact that carbohydrate metabolism, even
when monitored by continuous glucose monitoring, in-
volves additional players, i.e. deglycation enzymes, ery-
throcytic processes such as the mean red blood cell age,
and glucokinase mutations [12, 42–44].
Expert associations, such as the American Diabetes Asso-
ciation or the International Diabetes Federation, current-
ly focus on precision medicine based on a large selection
of laboratory assays, the ratios among them, and are inte-
gral part of such big data sets. Metabolic syndrome encom-
passes stages of diabetes mellitus, hypertriglyceridaemia
and hypertension, and it also might involve HNF1 home-
obox B, which controls transcription factors such as tu-
mour necrosis factor-1α in the context of immunological
changes in type 2 diabetes mellitus [45]. The cohort of SE-
NIORLABOR is homogenous by race, allowing us to ex-
Figure 5: Relationship between fructosamine and HbA1c.This 4-panel figure compares glycated haemoglobin A1c and fructosamine levels in
three different fructosamine concentration ranges (data from 1431 participants). A all participants. B subjects with fructosamine concentrations
<205 μmol/l. The glycated haemoglobin A1c values range from 4.5% to 7.0%. C Participants exhibiting fructosamine values within the refer-
ence interval. Glycated haemoglobin A1c values are within a narrow window. D individuals with high fructosamine levels have glycated
haemoglobin A1c values between 5.8% and 11%.
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clude the impact of ethnic/major genetic diversity, which
is known to play a role in maturity onset diabetes of the
young (www.diabetesgenes.org), as this won’t have a sub-
stantial influence on fasting glucose changes over time
in non-diabetic individuals of European descent [46]. The
performance of the pancreatic glucose sensor might influ-
ence the pattern of our results. We used homeostasis mod-
el assessment to assess insulin resistance, which is known
to increase with aging. The effect of age was previously
analysed separately in individuals with and without type 2
diabetes [25, 47]. This analysis also revealed gender dif-
ferences in homeostasis model assessment for estimation
of insulin resistance cut-off values in non-diabetic women
of 19% when using the Youden Index. We here describe
these gender differences without offering an explanation.
Whereas disciplined nutritional habits can be assumed in
the examined study population, the limited increments in
HbA1c values observed here might be caused by anti-dia-
betic drug overdosage or one of the following enhancers/
depressors of HbA1c results: haemoglobin gene variations,
even when clinically silent [48], mild haemolytic anaemia,
or folic acid deficiency. Thus, the pilot Spanish epidemi-
ology of chronic renal disease cross-sectional study [47] is
consistent with the present findings of a clear distinction
between female and male metabolisms. The Adult Treat-
ment Panel III criteria for metabolic syndrome include: ab-
dominal obesity (given as waist circumference >102 cm
for men and >88 cm for women), high-density lipoprotein-
associated cholesterol (men <1.0 mmol/l, women <1.3
mmol/l), blood pressure ≥130/≥85 mm Hg, fasting plasma
glucose ≥6.1 mmol/l, and triglyceride concentration ≥1.7
mmol/l. Being overweight or obese is also associated with
insulin resistance and the diagnosis of metabolic syndrome
[49].
Our separate consideration of four categories of glycation
gap, i.e., two below and two above zero, was borrowed
from earlier studies. We choose this method in order to
draw an error grid [38] and made it clear that the incremen-
tal values from negative to positive indicated progression
from a healthy to a diabetic metabolism. This finding pre-
sents evidence that the glycation gap is affected by the gly-
cation of both short-lived and long-lived proteins and re-
flects current and past glycation history.
One limitation to our study is the current uncertainty about
the best method for measuring glycation, e.g., by high-
power liquid chromatography, capillary electrophoresis or
immunological and enzymatic assays controlled by refer-
ence laboratorys [50]. More recently, the constitution of
the glycated haemoglobin has been scrutinised as a previ-
ously unknown influence on glycated haemoglobin A1c re-
sults. Racial differences also affect this variable [48]. Ef-
forts to comply with International Federation of Clinical
Chemistry reference systems and to improve biosensing
methods are maintained though [14]. Indeed, the nitrob-
lue tetrazolium reduction we used consists of reducing ana-
lytes commonly named ‘fructosamine’, but nitroblue tetra-
zolium is also an active oxygen species that produces a
formazan dye which any unbound sugar molecule in the
sample would convert. Some researchers prefer the mea-
surement of glycated albumin, which is largely in agree-
ment with fructosamine [51]. The need to improve the
management of diabetes makes advances in measurement
technology for glycated proteins necessary. It has been
suggested that variations in the level of the deglycating en-
zyme fructosamine-3-kinase, with its genetic locus, play a
role in glycation gap variations [52].
The uneven distribution of the non-diabetic and type 2 di-
abetes mellitus patients and the low number of type 2 dia-
betes patients in the negative glycation gap categories may
have led to underestimates of the below zero categories in
such patients. It also allows us to assume that HbA1c [53]
remains a more reliable risk predictor than glycation gap
alone [53, 54].
Alcohol consumption above one drink (10 g alcohol) daily
was an exclusion criterion for this study. Hence, the effects
of downstream sequelae of hepatic insulin resistance-im-
plicating lipid species such as triglyceride, inflammatory
signalling or other modifications [55] on the homeostasis
model assessment for insulin resistance here observed can-
not be excluded.
In conclusion, appreciation of the uneven chemical pro-
tein-based glycoconjugation of N-terminal glycation dur-
ing senescence and along different degrees of glucose me-
tabolism impairment remains in focus thanks to improved
laboratory technology. It remains inappropriate, from the
data presented here, to propose glycation gap measure-
ments for clinical care, although glycation gap and HbA1c
measurements point to a difference between HbA1c and
other measures of mean glycaemia [20]. This confers on
the glycation gap and its calculation a meaning regarding
the appreciation of the homoeostasis of glucose metabo-
lism. New markers for metabolic abnormalities now in-
clude the glycation gap, and studying the extent of glyca-
tion, up to advanced glycation end products, might help to
distinguish biological from chronological aging [56–58].
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